The weekly litigation news digest is live. Subscribe now
Use Of Long-Acting Glp-1 Peptides - EP3689365
The patent EP3689365 was granted to Novo Nordisk on Aug 6, 2025. The application was originally filed on Jun 21, 2013 under application number EP20157813A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3689365
- Application Number
- EP20157813A
- Filing Date
- Jun 21, 2013
- Status
- Granted And Under Opposition
- Jul 4, 2025
- Publication Date
- Aug 6, 2025
- External Links
- Slate, Register, Google Patents
Patent Summary
Improved GLP-1 agonist therapy for type 2 diabetes and obesity, comprising once-weekly administration of semaglutide in doses of 0.4-1.6 mg, which provides superior glycemic control and weight loss compared to daily liraglutide doses. The therapy is characterized by a prolonged half-life, enhanced stability against gastrointestinal enzymes, and improved potency in stimulating GLP-1 receptor activity.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (22) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents